Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry of Science and Technology of the People´s Republic of China | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China. Although their efficacy for acute phase are all better than typicals, individulized regimen of them for first-episode schizophrenia and their effectiveness in real naturalistic clinical settings still remain unclear. And those patients also need more comprehensive intervention such as psychosocial programs to improve their function. This protocol is to conduct a study in several sites of China to investigate the effectiveness of comprehensive intervention combining sequenced atypical antipsychotic therapy and intensive psychosocial intervention for first-episode schizophrenic patients. In addition, this protocol also aims at collecting such information as molecular genetics, neurochemical test, neucognitive performance and neuroimaging for outcome analysis.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Risperidone, Intensive | Experimental | risperidone and intensive psychosocial intervention |
|
| risperidone, basic | Active Comparator | risperidone and basic psychosocial support |
|
| olanzapine, intensive | Experimental | olanzapine and intensive psychosocial intervention |
|
| olanzapine, basic | Active Comparator | olanzapine and basic psychosocial support |
|
| aripiprazole, intensive | Experimental | aripiprazole and intensive psychosocial intervention |
|
| aripiprazole, basiv | Active Comparator | aripiprazole and basic psychosocial support |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| risperidone | Drug | 3-6 mg per day |
| |
| Measure | Description | Time Frame |
|---|---|---|
| the time the patients remain stable | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Scoring of PANSS and PSP | 1 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yanbo Yuan, M.D. | Contact | +8613910821507 | yuanyb@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Xin Yu, M.D. | Peking University Institute of Mental Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Anding Hospital | Recruiting | Beijing | Beijing Municipality | 100000 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41345405 | Derived | Yin X, Zhou T, Huang B, Lu Z, Gao T, Guo X, Hu W, Ji Y, Wang X, Zheng Y, Yu X, Pu C. Trajectory analysis of BMI increase induced by second-generation antipsychotics in first-episode schizophrenia: a secondary analysis based on CNFEST***. Schizophrenia (Heidelb). 2025 Dec 4;12(1):7. doi: 10.1038/s41537-025-00710-1. | |
| 38053101 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D018967 | Risperidone |
| D000077152 | Olanzapine |
| D000068180 | Aripiprazole |
| ID | Term |
|---|---|
| D011744 | Pyrimidinones |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| olanzapine |
| Drug |
5-20 mg per day |
|
| Aripiprazole | Drug | 10-30 mg per day |
|
| Beijing Huilongguan Hospital | Recruiting | Beijing | Beijing Municipality | 100000 | China |
|
| Peking University Institute of Mental Health | Recruiting | Haidian District | Beijing Municipality | 100191 | China |
|
| Zhongnan University Xiangya Second Hospital | Recruiting | Changsha | Hunan | 410000 | China |
|
| Shanghai Mental Health Center | Recruiting | Shanghai | Shanghai Municipality | 200030 | China |
|
| Sichuan University Huaxi Hospital | Recruiting | Chengdu | Sichuan | 610000 | China |
|
| Dai N, Huang B, Gao T, Zheng Y, Shi C, Pu C, Yu X. Initial attitudes toward a drug predict medication adherence in first-episode patients with schizophrenia: a 1-year prospective study in China. BMC Psychiatry. 2023 Dec 5;23(1):907. doi: 10.1186/s12888-023-05419-y. |
| 32636771 | Derived | Cheng Z, Yuan Y, Han X, Yang L, Zeng X, Yang F, Lu Z, Wang C, Deng H, Zhao J, Yu X. Which Subgroup of First-Episode Schizophrenia Patients Can Remit During the First Year of Antipsychotic Treatment? Front Psychiatry. 2020 Jun 19;11:566. doi: 10.3389/fpsyt.2020.00566. eCollection 2020. |
| 25482837 | Derived | Han X, Yuan YB, Yu X, Zhao JP, Wang CY, Lu Z, Yang FD, Dong H, Wu YF, Ungvari GS, Xiang YT, Chiu HF. The Chinese First-Episode Schizophrenia Trial: background and study design. East Asian Arch Psychiatry. 2014 Dec;24(4):169-73. |
| D001569 |
| Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010879 | Piperazines |
| D015363 | Quinolones |
| D011804 | Quinolines |